Skip to main content

Table 1 Association between clinical characteristics and EGFR and ALK status in the testing cohort

From: Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Characteristics

EGFR

ALK

Wild-type

Mutant-type

P value

Wild-type

Mutant-type

P value

Age, years

  

0.390

  

 < 0.001

 Median

61

60

 

61

54

 

 Range

23–88

31–86

 

23–88

27–81

 

Gender

  

 < 0.001

  

0.337

 Female

495 (72.37)

321 (41.15)

 

783 (56.01)

33 (50.00)

 

 Male

189 (27.63)

459 (58.85)

 

615 (43.99)

33 (50.00)

 

Smoking history

  

 < 0.001

  

0.121

 Never-smoker

345 (50.51)

635 (81.41)

 

930 (66.57)

50 (75.76)

 

 Ever-smoker

338 (49.49)

145 (18.59)

 

467 (33.43)

16 (24.24)

 

Pathology

  

 < 0.001

  

0.036

 Adenocarcinoma

585 (85.53)

753 (96.54)

 

1273 (91.06)

65 (98.48)

 

 Non-adenocarcinoma

99 (14.47)

27 (3.46)

 

125 (8.94)

1 (1.52)

 

AFP

  

0.104

  

1.000

 Negative

538 (98.18)

642 (99.23)

 

1126 (98.69)

54 (100.00)

 

 Positive

10 (1.82)

5 (0.77)

 

15 (1.31)

0 (0.00)

 

CEA

  

0.014

  

0.060

 Negative

341 (50.52)

342 (44.07)

 

645 (46.54)

38 (58.46)

 

 Positive

334 (49.48)

434 (55.93)

 

741 (53.46)

27 (41.54)

 

CA125

  

 < 0.001

  

0.164

 Negative

319 (48.41)

458 (59.87)

 

748 (54.96)

29 (46.03)

 

 Positive

340 (51.59)

307 (40.13)

 

613 (45.04)

34 (53.97)

 

CA19-9

  

0.031

  

0.530

 Negative

493 (75.61)

610 (80.37)

 

1055 (78.32)

48 (75.00)

 

 Positive

159 (24.39)

149 (19.63)

 

292 (21.68)

16 (25.00)

 

CA15-3

  

0.195

  

 < 0.001

 Negative

451 (75.04)

542 (78.10)

 

962 (77.64)

31 (55.36)

 

 Positive

150 (24.96)

152 (21.90)

 

277 (22.36)

25 (44.64)

 

FERR

  

 < 0.001

  

0.135

 Negative

210 (55.56)

289 (68.16)

 

471 (61.65)

28 (73.68)

 

 Positive

168 (44.44)

135 (31.84)

 

293 (38.35)

10 (26.32)

 

CA72-4

  

0.010

  

0.209

 Negative

289 (72.43)

369 (79.87)

 

630 (76.83)

28 (68.29)

 

 Positive

110 (27.57)

93 (20.13)

 

190 (23.17)

13 (31.71)

 

PSA

  

0.610

  

0.711

 Negative

262 (91.93)

165 (93.22)

 

403 (92.22)

24 (96.00)

 

 Positive

23 (8.07)

12 (6.78)

 

34 (7.78)

1 (4.00)

 

FPSA

  

0.436

  

1.000

 Negative

272 (95.44)

166 (93.79)

 

414 (94.74)

24 (96.00)

 

 Positive

13 (4.56)

11 (6.21)

 

23 (5.26)

1 (4.00)

 

SCC

  

 < 0.001

  

0.178

 Negative

472 (76.62)

636 (90.34)

 

1063 (84.23)

45 (77.59)

 

 Positive

144 (23.38)

68 (9.66)

 

199 (15.77)

13 (22.41)

 

CYFRA 21-1

  

 < 0.001

  

0.137

 Negative

216 (35.64)

332 (47.91)

 

519 (41.75)

29 (51.79)

 

 Positive

390 (64.36)

361 (52.09)

 

724 (58.25)

27 (48.21)

 

NSE

  

0.034

  

0.472

 Negative

212 (44.17)

268 (50.85)

 

460 (47.92)

20 (42.55)

 

 Positive

268 (55.83)

259 (49.15)

 

500 (52.08)

27 (57.45)

 

TTF-1

  

 < 0.001

  

0.145

 Negative

129 (20.48)

14 (2.04)

 

140 (11.13)

3 (5.08)

 

 Positive

501 (79.52)

673 (97.96)

 

1118 (88.87)

56 (94.92)

 

Napsin A

  

 < 0.001

  

0.401

 Negative

121 (28.67)

19 (5.23)

 

135 (18.10)

5 (12.82)

 

 Positive

301 (71.33)

344 (94.77)

 

611 (81.90)

34 (87.18)

 

CK-7

  

0.006

  

1.000

 Negative

19 (5.79)

3 (1.27)

 

21 (3.94)

1 (3.13)

 

 Positive

309 (94.21)

234 (98.73)

 

512 (96.06)

31 (96.88)

 

Ki67

  

0.083

  

0.528

 Negative

37 (28.03)

28 (40.00)

 

60 (31.58)

5 (41.67)

 

 Positive

95 (71.97)

42 (60.00)

 

130 (68.42)

7 (58.33)

 
  1. Values presented are n (%) unless otherwise noted
  2. EGFR epidermal growth factor receptor; ALK anaplastic lymphoma kinase; AFP alpha fetoprotein; CEA carcinoembryonic antigen; CA carbohydrate antigen; FERR ferritin; PSA prostate specific antigen; FPSA free prostate specific antigen; SCC squamous cell carcinoma antigen; CYFRA 21-1 soluble fragment of cytokeratin 19; NSE neuron-specific enolase; TTF-1 thyroid transcription factor-1; CK-7 cytokeratin-7